Generare
Develops technology for healthcare and life-sciences teams to produce novel molecules at higher scale, targeting a 10x increase by 2027.
Overview
Generare develops technology focused on producing novel molecules for healthcare and life-sciences applications. Its stated ambition is to increase novel molecule output by 10x by 2027, positioning the company around higher-throughput discovery and production. The company raised a €20M Series A in April 2026, co-led by Alven and Daphni. The round represents its disclosed total funding to date and supports Generare’s push to scale molecule generation.
Funding History
Alven and Daphni co-lead Generare’s €20M to produce 10x novel molecules by 2027
Frequently Asked Questions
- How much funding does AI Funding track for Generare?
- AI Funding tracks €20M for Generare across 1 funding round in this database.
- Who are Generare's investors?
- Generare's investors include Alven, Daphni, Galion.exe, Teampact Ventures, VIVES Partners.
- What does Generare do?
- Generare develops technology focused on producing novel molecules for healthcare and life-sciences applications. Its stated ambition is to increase novel molecule output by 10x by 2027, positioning the company around higher-throughput discovery and production. The company raised a €20M Series A in April 2026, co-led by Alven and Daphni. The round represents its disclosed total funding to date and supports Generare’s push to scale molecule generation.
- Where is Generare headquartered?
- Generare is headquartered in Paris, France.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.